PRKAA1 and ovarian cancer: Therefore, inhibition of TAK1/NF-κB signaling by 5Z-O or suppression of AMPK/ACC/FASN signaling in lipogenesis by the potent AMPK activator PF-0640957752 or orlistat could inhibit ovarian cancer dissemination and tumor growth in vivo.